Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Diabeloop is a medical technology company that develops innovative artificial intelligence-based solutions to automate and personalize diabetes management. Their primary focus is on improving the quality of life for people with type 1 diabetes through closed-loop systems that connect continuous glucose monitors (CGMs) and insulin pumps. Diabeloop's CE-marked systems, like DBLG1 and DBL-hu, aim to reduce the daily burden of diabetes by providing automated insulin delivery, thus helping to stabilize blood glucose levels and reduce hypoglycemic and hyperglycemic episodes. The company collaborates closely with patients, healthcare professionals, and research institutions to develop user-centric and clinically effective technologies.
The Grenoble headquarters serves as the central hub for Diabeloop's research and development, strategic planning, global operations, and administrative functions. It's where their core AI algorithms and diabetes management solutions are conceived and refined.
The headquarters is likely located within a technology-focused business park, featuring modern office spaces, R&D laboratories equipped for medical device development, and collaborative environments designed to foster innovation.
Diabeloop's HQ likely fosters a highly collaborative, innovative, and patient-centric work culture. Employees are driven by a mission to improve the lives of people with diabetes, with a strong emphasis on scientific rigor, technological advancement, and interdisciplinary teamwork.
The Grenoble location is significant due to its proximity to leading research institutions, a skilled talent pool in engineering and medical technology, and a supportive ecosystem for high-tech startups. This environment is crucial for Diabeloop's cutting-edge R&D in therapeutic AI.
Diabeloop is headquartered in Grenoble, France, with key offices in Paris, France, and Menlo Park, California, USA. While core R&D and product development are centered in France, the company has established a commercial presence across several European countries including Germany, the Netherlands, Italy, Spain, and Switzerland. Its expansion into the United States and collaborations in markets like Japan signify its growing global reach. Diabeloop supports functions like clinical research, regulatory affairs, sales, marketing, and customer support internationally to make its AI-driven diabetes solutions accessible to a wider patient population.
17 Rue Félix Esclangon
Grenoble
Auvergne-Rhône-Alpes
France
Address: 5 Rue de la Baume, 75008 Paris
Serves as a strategic hub for national and potentially European commercial activities, communication, and networking within the French healthcare ecosystem.
Address: 101 Jefferson Drive, 1st Floor, Menlo Park, CA 94025
Key for accessing the significant US diabetes market, engaging with US-based research institutions, healthcare providers, and navigating the American regulatory landscape.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Diabeloop' leadership includes:
Diabeloop has been backed by several prominent investors over the years, including:
Diabeloop has strategically reinforced its leadership over the past year, notably by appointing a new Chief Financial Officer and a Head of Legal & Compliance. These key hires are aimed at supporting the company's ongoing growth, international expansion, and navigation of complex regulatory landscapes in the medical technology sector.
Discover the tools Diabeloop uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Diabeloop primarily uses the `first.last@diabeloop.com` email format for its employees. This is a common structure for professional communication within technology and healthcare companies and has been observed in public communications from the company.
first.last@diabeloop.com
Format
jane.doe@diabeloop.com
Example
90%
Success rate
Diabeloop Official Website • April 24, 2024
A real-world study of Diabeloop's DBLG1 system demonstrated significant and sustained improvements in glycemic control for individuals with Type 1 diabetes, highlighting its effectiveness in everyday life....more
Diabeloop Official Website • February 27, 2024
Diabeloop and Terumo Corporation are strengthening their collaboration to expedite the launch of an automated insulin delivery (AID) system featuring a patch pump in Japan, aiming to enhance diabetes care in the region....more
Diabeloop Official Website • December 5, 2023
Diabeloop announced it has received clearance from the U.S. Food and Drug Administration (FDA) for DBL-Easy, its software application designed to be used with smart insulin pens for people with type 1 or type 2 diabetes....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Diabeloop, are just a search away.